Blog
    Regulatory UpdateFor PhysiciansSeptember 18, 2026

    Peptide Regulatory Update: FDA Status and Safety Signals

    Review recent FDA regulatory shifts for BPC-157 and GLP-1 safety signals including gastrointestinal, renal, and emerging ophthalmic concerns.

    Clinical Question

    What are the current FDA regulatory statuses for common therapeutic peptides, and what safety signals have been identified in recent clinical data and postmarketing surveillance?

    Evidence Snapshot

    • Regulatory Status: Multiple peptides including BPC-157, CJC-1295, and Ipamorelin are designated as Category 2 bulk substances.
    • FDA Warning Letters: Issued to entities such as Tailor Made Compounding (2020) and Predator Nutrition (Oct 2020) regarding various peptide products.
    • Safety Signals (Semaglutide): Strong signals for nausea, vomiting, and delayed gastric emptying; emerging signals for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and pulmonary aspiration.
    • Clinical Trial Outcomes: Weight loss ranging from 14.9% (Semaglutide) to 24.2% (Retatrutide) in Phase II/III trials; negative Phase III results for Thymosin Alpha-1 in sepsis.

    What the Research Shows

    Regulatory oversight of peptide substances has shifted significantly. As of March 2026, the FDA has classified several peptides as Category 2 substances, indicating they are ineligible for routine compounding due to significant safety risks or a lack of safety data. For instance, BPC-157 is listed in Category 2 with concerns regarding immunogenicity and a lack of safety data. Similarly, TB-500 is noted for immunogenicity risk and a lack of human exposure data.

    Several compounds previously nominated for compounding, such as CJC-1295, AOD-9604, and Ipamorelin, had their nominations withdrawn or were removed from consideration in September 2024. The FDA specifically cited safety issues like increased heart rate for CJC-1295.

    In clinical safety monitoring for Semaglutide, FAERS data through 2023 includes 187,757 reports for GLP-1 receptor agonists. Strong signals are established for gastrointestinal effects including nausea, vomiting, and delayed gastric emptying. The latter has led to label updates regarding the risk of pulmonary aspiration during general anesthesia. A moderate signal exists for acute pancreatitis, and a signal has been detected for acute kidney injury, often occurring in the context of dehydration.

    Emerging safety signals for Semaglutide include NAION (96 cases through December 2024), which was placed under EMA review in January 2025. Psychiatric monitoring for suicidal ideation is required by the FDA, though current data does not support a higher risk compared to background rates.

    Clinical trials have demonstrated varying efficacy and safety profiles. The STEP 1 trial for Semaglutide showed 14.9% weight loss, while the SURMOUNT-1 trial for Tirzepatide reported 22.5%. Retatrutide showed 24.2% weight loss at 12mg in Phase II. However, some trials have yielded negative results; a Phase III trial for Thymosin Alpha-1 in sepsis showed no reduction in mortality.

    Mechanism

    According to regulatory and clinical records, specific safety mechanisms identified include:

    • Immunogenicity: Cited as a primary concern for BPC-157, TB-500, and GHRP-2.
    • Gastrointestinal Transit: Delayed gastric emptying is a documented mechanism for Semaglutide, which may impact oral medication absorption and contribute to aspiration risk.
    • Cardiovascular: Increased heart rate is cited as a safety issue for CJC-1295.
    • Weight Loss-Related: Cholelithiasis and cholecystitis signals are associated with rapid weight loss during GLP-1 therapy.

    Limitations of the Evidence

    There is a notable lack of human exposure data for several peptides, including TB-500. While Thymosin Alpha-1 and Selank have received approvals in other countries (such as Russia or a group of 35+ countries for Zadaxin), they are not FDA-approved. Many safety signals, such as NAION and pulmonary aspiration, are emerging from postmarketing surveillance and require further formal review to establish definitive causality. For substances like BPC-157, the FDA explicitly notes a lack of sufficient safety data.

    Clinical Takeaway

    Regulatory authorities have tightened restrictions on many non-approved peptides, moving them to Category 2 status due to safety concerns like immunogenicity. Clinicians should be aware of the strong gastrointestinal safety signals and emerging ophthalmic and pulmonary risks associated with approved GLP-1 therapies. The status of these substances is subject to ongoing review, as seen with the September 2024 removals and withdrawals of several compounding nominations. This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Clinicians seeking to understand how these regulatory changes affect their practice can consult a specialized peptide therapy clinic for further information. You may also find a doctor who specializes in metabolic and regulatory medicine to discuss individual patient needs.

    Sources

    1. FDA Regulatory Status Records (BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, etc.), as of March 2026.
    2. FAERS Safety Signal Database (Semaglutide), 2023-2025.
    3. Clinical Trial Records (NCT03548935, NCT04184622, NCT04881706, NCT02867267, etc.).

    Referenced Peptides

    bpc 157thymosin alpha 1cjc 1295tb 500semaglutidetirzepatide

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.